



OPA1: How much do we know to approach therapy?

Submitted by Guy Lenaers on Sat, 12/22/2018 - 17:37

Titre OPA1: How much do we know to approach therapy?

Type de publication Article de revue

Auteur Del Dotto, Valentina [1], Fogazza, Mario [2], Lenaers, Guy [3], Rugolo, Michela [4], Carelli, Valerio [5], Zanna, Claudia [6]

Editeur Elsevier

Type Article scientifique dans une revue à comité de lecture

Année 2018

Langue Anglais

Date Mai 2018

Pagination 199-210

Volume 131

Titre de la revue Pharmacological research

ISSN 1096-1186

Mots-clés DOA therapy [7], dominant optic atrophy [8], Mitochondria dynamics [9], OPA1 mutations [10]

Résumé en anglais OPA1 is a GTPase that controls several functions, such as mitochondrial dynamics and energetics, mtDNA maintenance and cristae integrity. In the last years, there have been described other cellular pathways and mechanisms involving OPA1 directly or through its interaction. All this new information, by implementing our knowledge on OPA1 is instrumental to elucidating the pathogenic mechanisms of OPA1 mutations. Indeed, these are associated with dominant optic atrophy (DOA), one of the most common inherited optic neuropathies, and with an increasing number of heterogeneous neurodegenerative disorders. In this review, we overview all recent findings on OPA1 protein functions, on its dysfunction and related clinical phenotypes, focusing on the current therapeutic options and future perspectives to treat DOA and the other associated neurological disorders due to OPA1 mutations.

URL de la notice <http://okina.univ-angers.fr/publications/ua18495> [11]

DOI 10.1016/j.phrs.2018.02.018 [12]

Lien vers le document <https://www.sciencedirect.com/science/article/abs/pii/S1043661817316171?...> [13]

Titre abrégé Pharmacol. Res.

Identifiant (ID) 29454676 [14]

PubMed

Liens

[1] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=32247>

[2] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=32248>

- [3] <http://okina.univ-angers.fr/guy.lenaers/publications>
- [4] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=516>
- [5] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=24173>
- [6] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=515>
- [7] <http://okina.univ-angers.fr/publications?f%5Bkeyword%5D=26670>
- [8] <http://okina.univ-angers.fr/publications?f%5Bkeyword%5D=6485>
- [9] <http://okina.univ-angers.fr/publications?f%5Bkeyword%5D=26669>
- [10] <http://okina.univ-angers.fr/publications?f%5Bkeyword%5D=26668>
- [11] <http://okina.univ-angers.fr/publications/ua18495>
- [12] <http://dx.doi.org/10.1016/j.phrs.2018.02.018>
- [13] <https://www.sciencedirect.com/science/article/abs/pii/S1043661817316171?via%3Dihub>
- [14] <http://www.ncbi.nlm.nih.gov/pubmed/29454676?dopt=Abstract>

Publié sur *Okina* (<http://okina.univ-angers.fr>)